Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,741 to 4,760 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: Composite of the Following: Acute/Urgent Care and/or Emergency Room Visits, Hospital Readmissions | 86 of 603 113 of 702 | -1.8 points -5.7 to 2.1 | 1,305 | NCT04057820 Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach |
| Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: Inpatient Composite Safety Outcome Which Includes Seizures, Accidental Trauma, Respiratory Insufficiency Due to Opioid Therapy (Present/Absent) | 2 of 603 1 of 702 | 0.2 points -0.5 to 1.1 | 1,305 | NCT04057820 Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach |
| Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: deaths from any cause | 0 of 603 4 of 702 | -0.6 points -1.5 to 0.2 | 1,305 | NCT04057820 Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach |
| Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: Did Infant Receive Opioid Replacement Therapy (Yes/no) | 145 of 603 328 of 702 | -22.7 points -27.6 to -17.6 | 1,305 | NCT04057820 Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach |
| Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: serious adverse events | 12 of 603 4 of 702 | 1.4 points 0.2 to 2.9 | 1,305 | NCT04057820 Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach |
| Participants 10 to <11 Years of Age vs Participants 11 to <12 Years of Age: serious adverse events | 0 of 651 1 of 651 | -0.2 points -0.9 to 0.4 | 1,302 | NCT01311557 Study of Adacel® Vaccine Administered to Persons 10 Years of Age |
| Darolutamide (BAY1841788) + Docetaxel vs Placebo + Docetaxel: deaths from any cause | 231 of 652 305 of 650 | -11.5 points -16.7 to -6.2 | 1,302 | NCT02799602 Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer |
| Darolutamide (BAY1841788) + Docetaxel vs Placebo + Docetaxel: serious adverse events | 306 of 652 276 of 650 | 4.5 points -0.9 to 9.8 | 1,302 | NCT02799602 Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer |
| FDA Approved Regimen vs MK-3475 (Pembrolizumab): deaths from any cause | 130 of 654 131 of 647 | -0.4 points -4.7 to 4.0 | 1,301 | NCT02506153 Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery |
| Atezolizumab With Paclitaxel, Carboplatin and Bevacizumab vs Placebo With Paclitaxel, Carboplatin and Bevacizumab: deaths from any cause | 272 of 651 289 of 650 | -2.7 points -8.0 to 2.7 | 1,301 | NCT03038100 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
| Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Cardiovascular Collapse | 113 of 645 127 of 656 | -1.8 points -6.1 to 2.4 | 1,301 | NCT05267652 Pragmatic Trial Examining Oxygenation Prior to Intubation |
| Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Successful Intubation on the First Attempt | 534 of 645 535 of 656 | 1.2 points -2.9 to 5.4 | 1,301 | NCT05267652 Pragmatic Trial Examining Oxygenation Prior to Intubation |
| Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: 28-day In-hospital Mortality | 209 of 645 217 of 656 | -0.7 points -5.8 to 4.4 | 1,301 | NCT05267652 Pragmatic Trial Examining Oxygenation Prior to Intubation |
| Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: deaths from any cause | 209 of 645 217 of 656 | -0.7 points -5.8 to 4.4 | 1,301 | NCT05267652 Pragmatic Trial Examining Oxygenation Prior to Intubation |
| Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: Incidence of Operator-reported Aspiration | 6 of 645 9 of 656 | -0.4 points -1.8 to 0.8 | 1,301 | NCT05267652 Pragmatic Trial Examining Oxygenation Prior to Intubation |
| Preoxygenation With Non-Invasive Positive Pressure Ventilation Group vs Preoxygenation With Facemask Oxygen Group: serious adverse events | 2 of 645 0 of 656 | 0.3 points -0.3 to 1.1 | 1,301 | NCT05267652 Pragmatic Trial Examining Oxygenation Prior to Intubation |
| TA-7284-Low vs TA-7284-High: serious adverse events | 30 of 584 32 of 715 | 0.7 points -1.7 to 3.1 | 1,299 | NCT01387737 Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus |
| MET and LIFE vs Healthy Lifestyle Intervention (LIFE): serious adverse events | 12 of 579 25 of 720 | -1.4 points -3.2 to 0.5 | 1,299 | NCT02515773 Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs |
| Cohort 1: Participants Aged 9 to 17 Years vs Cohort 2: Participants Aged 18 to 49 Years: Number of Participants With Immediate Unsolicited Adverse Events (AEs) | 1 of 641 0 of 658 | 0.2 points -0.4 to 0.9 | 1,299 | NCT05513053 Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age. |
| Cohort 1: Participants Aged 9 to 17 Years vs Cohort 2: Participants Aged 18 to 49 Years: Number of Participants With Unsolicited AEs | 93 of 641 119 of 658 | -3.6 points -7.6 to 0.4 | 1,299 | NCT05513053 Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age. |
Code
curl "https://conductscience.org/api/comparisons/v1?page=238"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=238
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04057820-52246e26",
"title": "Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: Composite of the Following: Acute/Urgent Care and/or Emergency Room Visits, Hospital Readmissions",
"summary": "86 of 603 against 113 of 702; risk difference -1.8 points, 95% interval -5.7 to 2.1; NCT04057820, Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach",
"record": "/library/comparisons/NCT04057820-52246e26",
"nct_id": "NCT04057820",
"kind": "outcome",
"participants": 1305,
"risk_difference": {
"value": -0.018348428796190003,
"lower": -0.05707986057198294,
"upper": 0.021049040310868655
},
"group_1": "86 of 603",
"group_2": "113 of 702",
"difference": "-1.8 points",
"interval": "-5.7 to 2.1",
"trial_title": "Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach"
},
{
"id": "NCT04057820-c8792884",
"title": "Eat, Sleep, Console Care Tool vs Usual Care, Finnegan Neonatal Abstinence Scoring Tool: Inpatient Composite Safety Outcome Which Includes Seizures, Accidental Trauma, Respiratory Insufficiency Due to Opioid Therapy (Present/Absent)",
"summary": "2 of 603 against 1 of 702; risk difference 0.2 points, 95% interval -0.5 to 1.1; NCT04057820, Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach",
"record": "/library/comparisons/NCT04057820-c8792884",
"nct_id": "NCT04057820",
"kind": "outcome",
"participants": 1305,
"risk_difference": {
"value": 0.0018922481609048773,
"lower": -0.005132748043640298,
"upper": 0.010665978153554937
},
"group_1": "2 of 603",
"group_2": "1 of 702",
"difference": "0.2 points",
"interval": "-0.5 to 1.1",
"trial_title": "Eating, Sleeping, Consoling for Neonatal Withdrawal (ESC-NOW): a Function-Based Assessment and Management Approach"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=239",
"request_id": "XHypzLzWzwi3ZwOI"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant